Explore Currently Enrolling Genentech and Roche Clinical Trials in Oncology

Search for clinical trials by making selections below.

Tumor Type View All

Breast Gastrointestinal Genitourinary Gynecologic Hematology Lung Melanoma Solid Tumor

Phase

III II I

Molecule*

Select...
Antibody drug conjugate (HER2-TDC) (RG6148) Antibody drug conjugate (RG6109) Anti-MUC16 TDC (RG7882) Atezolizumab (anti-PDL1 MAb) (RG7446) BET inhibitor (TEN-010, RG6146) Bevacizumab (anti-VEGF MAb) CD20 x CD3 (RG6026) Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) ChK1 inhibitor (GDC-0575, RG7741) Cibisatamab (CEA x CD3) (RG7802) Cobimetinib (MEK inhibitor) (RG7421) Codrituzumab (anti–glypican 3 MAb) (CHU, RG7686) Emactuzumab (anti–CSF-1R MAb) (RG7155) Entrectinib (ROS1/TRK inhibitor) (RXDX-101, RG6268) Etrolizumab (RG7413) FAP-4-1BBL FP (RG7827) FAP-DR5 biMAb (RG7386) FAP-IL2v FP (RG7461) Fixed dose combination SC pertuzumab + trastuzumab (anti-HER2 MAb) (RG6264) Glypican-3 x CD3 (CHU) HER2 x CD3 (RG6194) Idasanutlin (MDM2 antagonist) (RG7388) Individualized NeoAntigen Specific Immunotherapy (iNeST) (RG6180) Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) Monoclonal antibody (RG6123) Monoclonal antibody (RG6160) Mosunetuzumab (CD20 x CD3) (RG7828) Obinutuzumab Pan-RAF inhibitor (RG6185) PD-1 x TIM3 (RG7769) PI3K inhibitor (GDC-0077, RG6114) PI3K inhibitor (RG6114) Polatuzumab vedotin (anti-CD79b ADC) (RG7596) Raf/MEK dual inhibitor (CHU) Selective estrogen receptor degrader (SERD[3]) (GDC-9545, RG6171) Selicrelumab (CD40 MAb) (RG7876) Taselisib (PI3K inhibitor) (GDC-0032, RG7604) Tiragolumab (anti-TIGIT MAb) (RG6058) Tocilizumab (RG1569) Vanucizumab (ANG2-VEGF biMAb) (RG7221) Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601)

US Region

International

Region

Select...
Clear All
View Results
Expand +

Tumor Type: Breast, Gastrointestinal, Genitourinary

Phase:

Region:

Molecule: Ipatasertib (AKT inhibitor) (GDC-0068, RG7440)

For more information about recruiting clinical trials, please call the Trial Information Support Line for US Clinical Trial information at 888-662-6728 or visit ClinicalTrials.gov.
Email your search results to yourself.
Clear All
View Results
Tumor Type Phase Molecule* Location Study Contact
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel AR NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel AR
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel AU NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel AU
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel BE NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel BE
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel BR NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel BR
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel CA NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel CA
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel CA NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel CA
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel CL NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel CL
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel DE NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel DE
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel ES NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel ES
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel FL NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel FL
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel FR NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel FR
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel GB NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel GB
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel GR NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel GR
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel HU NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel HU
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel IN NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel IN
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel IT NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel IT
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel JP NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel JP
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel KR NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel KR
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel MA NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel MA
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel MD NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel MD
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel MX NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel MX
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel NA NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel NA
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel NY NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel NY
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel OR NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel OR
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel PE NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel PE
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel PL NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel PL
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel RU NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel RU
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel SG NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel SG
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel SI NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel SI
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel TN NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel TN
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel TR NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel TR
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel TW NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel TW
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel TX NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel TX
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel UA NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel UA
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel ZA NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Breast III, II Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel ZA
NCT03337724—A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Capecitabine, Cobimetinib (MEK inhibitor) (RG7421), FAP-IL2v FP (RG7461), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Selicrelumab (CD40 MAb) (RG7876) AU NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC)
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Capecitabine, Cobimetinib (MEK inhibitor) (RG7421), FAP-IL2v FP (RG7461), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Selicrelumab (CD40 MAb) (RG7876) AU
NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC)
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Capecitabine, Cobimetinib (MEK inhibitor) (RG7421), FAP-IL2v FP (RG7461), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Selicrelumab (CD40 MAb) (RG7876) CA NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC)
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Capecitabine, Cobimetinib (MEK inhibitor) (RG7421), FAP-IL2v FP (RG7461), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Selicrelumab (CD40 MAb) (RG7876) CA
NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC)
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Capecitabine, Cobimetinib (MEK inhibitor) (RG7421), FAP-IL2v FP (RG7461), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Selicrelumab (CD40 MAb) (RG7876) DE NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC)
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Capecitabine, Cobimetinib (MEK inhibitor) (RG7421), FAP-IL2v FP (RG7461), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Selicrelumab (CD40 MAb) (RG7876) DE
NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC)
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Capecitabine, Cobimetinib (MEK inhibitor) (RG7421), FAP-IL2v FP (RG7461), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Selicrelumab (CD40 MAb) (RG7876) ES NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC)
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Capecitabine, Cobimetinib (MEK inhibitor) (RG7421), FAP-IL2v FP (RG7461), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Selicrelumab (CD40 MAb) (RG7876) ES
NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC)
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Capecitabine, Cobimetinib (MEK inhibitor) (RG7421), FAP-IL2v FP (RG7461), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Selicrelumab (CD40 MAb) (RG7876) FL NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC)
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Capecitabine, Cobimetinib (MEK inhibitor) (RG7421), FAP-IL2v FP (RG7461), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Selicrelumab (CD40 MAb) (RG7876) FL
NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC)
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Capecitabine, Cobimetinib (MEK inhibitor) (RG7421), FAP-IL2v FP (RG7461), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Selicrelumab (CD40 MAb) (RG7876) FR NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC)
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Capecitabine, Cobimetinib (MEK inhibitor) (RG7421), FAP-IL2v FP (RG7461), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Selicrelumab (CD40 MAb) (RG7876) FR
NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC)
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Capecitabine, Cobimetinib (MEK inhibitor) (RG7421), FAP-IL2v FP (RG7461), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Selicrelumab (CD40 MAb) (RG7876) GB NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC)
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Capecitabine, Cobimetinib (MEK inhibitor) (RG7421), FAP-IL2v FP (RG7461), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Selicrelumab (CD40 MAb) (RG7876) GB
NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC)
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Capecitabine, Cobimetinib (MEK inhibitor) (RG7421), FAP-IL2v FP (RG7461), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Selicrelumab (CD40 MAb) (RG7876) KR NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC)
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Capecitabine, Cobimetinib (MEK inhibitor) (RG7421), FAP-IL2v FP (RG7461), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Selicrelumab (CD40 MAb) (RG7876) KR
NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC)
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Capecitabine, Cobimetinib (MEK inhibitor) (RG7421), FAP-IL2v FP (RG7461), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Selicrelumab (CD40 MAb) (RG7876) NJ NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC)
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Capecitabine, Cobimetinib (MEK inhibitor) (RG7421), FAP-IL2v FP (RG7461), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Selicrelumab (CD40 MAb) (RG7876) NJ
NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC)
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Capecitabine, Cobimetinib (MEK inhibitor) (RG7421), FAP-IL2v FP (RG7461), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Selicrelumab (CD40 MAb) (RG7876) NY NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC)
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Capecitabine, Cobimetinib (MEK inhibitor) (RG7421), FAP-IL2v FP (RG7461), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Selicrelumab (CD40 MAb) (RG7876) NY
NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC)
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Capecitabine, Cobimetinib (MEK inhibitor) (RG7421), FAP-IL2v FP (RG7461), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Selicrelumab (CD40 MAb) (RG7876) PA NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC)
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Capecitabine, Cobimetinib (MEK inhibitor) (RG7421), FAP-IL2v FP (RG7461), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Selicrelumab (CD40 MAb) (RG7876) PA
NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC)
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Capecitabine, Cobimetinib (MEK inhibitor) (RG7421), FAP-IL2v FP (RG7461), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Selicrelumab (CD40 MAb) (RG7876) TN NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC)
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Capecitabine, Cobimetinib (MEK inhibitor) (RG7421), FAP-IL2v FP (RG7461), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Selicrelumab (CD40 MAb) (RG7876) TN
NCT03424005—A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC)
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) AL NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) AL
NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) CA NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) CA
NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) IL NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) IL
NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) KR NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) KR
NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) MD NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) MD
NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) NC NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) NC
NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) NY NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) NY
NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) OH NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) OH
NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) OR NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) OR
NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) PA NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) PA
NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) TN NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) TN
NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) TX NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Breast II, I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF MAb), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) TX
NCT03280563—A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel AU NCT03800836—A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel AU
NCT03800836—A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel CA NCT03800836—A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel CA
NCT03800836—A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel ES NCT03800836—A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel ES
NCT03800836—A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel FR NCT03800836—A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel FR
NCT03800836—A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel GB NCT03800836—A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Breast I Atezolizumab (anti-PDL1 MAb) (RG7446), Ipatasertib (AKT inhibitor) (GDC-0068, RG7440), Paclitaxel GB
NCT03800836—A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Tumor
Type
Phase Molecule* Location
Breast I Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) AU NCT03840200—A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
Breast I Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) AU
NCT03840200—A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
Tumor
Type
Phase Molecule* Location
Breast I Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) ES NCT03840200—A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
Breast I Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) ES
NCT03840200—A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
Tumor
Type
Phase Molecule* Location
Breast I Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) IT NCT03840200—A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
Breast I Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) IT
NCT03840200—A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
Tumor
Type
Phase Molecule* Location
Breast I Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) PA NCT03840200—A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
Breast I Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) PA
NCT03840200—A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) BR NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) BR
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) ES NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) ES
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) FL NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) FL
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) IT NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) IT
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary III Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) JP NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Genitourinary III Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) JP
NCT03072238—Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Tumor
Type
Phase Molecule* Location
Genitourinary I Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) AU NCT03840200—A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
Genitourinary I Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) AU
NCT03840200—A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
Tumor
Type
Phase Molecule* Location
Genitourinary I Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) ES NCT03840200—A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
Genitourinary I Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) ES
NCT03840200—A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
Tumor
Type
Phase Molecule* Location
Genitourinary I Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) IT NCT03840200—A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
Genitourinary I Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) IT
NCT03840200—A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
Tumor
Type
Phase Molecule* Location
Genitourinary I Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) PA NCT03840200—A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
Genitourinary I Ipatasertib (AKT inhibitor) (GDC-0068, RG7440) PA
NCT03840200—A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
1 of 77 clinical trials
1-4 of 77 clinical trials
ClickTap on the NCT numbers above to visit ClinicalTrials.gov for further details about each trial, including eligibility criteria, primary and secondary outcome measures, and contacts and locations.
This website is intended for US healthcare professionals and contains information on investigational compounds and drug uses that have not been approved by the FDA. Click "OK" if you are a healthcare professional and wish to proceed.
CancelOK
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech. Genentech makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.
CancelContinue
The list of international studies is not comprehensive; only international studies that also include actively enrolling US sites are listed.

Click "OK" if you wish to proceed.
CancelOK